Kymab wins Supreme Court case against Regeneron
The ‘landmark’ decision invalidates Regeneron’s patent claims covering its genetically modified mice
Read More
Tag: Kymab
Kymab, LifeArc form medicines discovery alliance
The partnership provides LifeArc with access to Kymab’s suite of antibody discovery technologies, including Darwin.
Read More
Kymab’s antibody shows early promise in GvHD prophylaxis
UK group Kymab has unveiled what it says are “remarkable” early stage results for its new antibody therapy KY1005 in animal models of acute graft-versus-host-disease (GvHD).
Read More
Kymab bags £18m investment for antibodies
UK monoclonal antibody biopharma Kymab has secured funds of £81 million via a round of Series C financing.
Read More
UK’s Kymab signs bispecific antibodies deal with China’s EpimAb
UK biopharma Kymab has signed a cross-licensing and development deal with Shanghai-based EpimAb Biotherapeutics to develop bispecific therapeutic antibodies against multiple targets.
Read More
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
